High-grade prostate cancer and finasteride

BJU International

Volumn 105, Issue 4, 2010, Pages 456-459

  Lebdai, Souhil ^a   Bigot, Pierre ^a   Azzouzi, Abdel Rahmène ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Finasteride; High grade cancer; PCPT trial; Prostatic neoplasms

Indexed keywords

ANDROSTANOLONE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; BLOOD SAMPLING; CANCER GRADING; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIGITAL RECTAL EXAMINATION; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SHORT SURVEY;

AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE; TREATMENT OUTCOME;

EID: 76149143134     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09089.x     Document Type: Short Survey

References (20)

1. Brawley OW, Ford LG, Thompson I, Perlman JA, Kramer BS. 5-Alpha-reductase inhibition and prostate cancer prevention. Cancer Epidemiol Biomarkers Prev 1994 3 : 177 182
2. Newling DW. Update on urology - prostate cancer. 1 - The molecular basis for prostatic cancer: how it may influence treatment choice. Eur J Surg Oncol 1995 21 : 310 315
3. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003 349 : 215 224
4. Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B. Prevention of prostate cancer with finasteride: US/European Perspective. Eur Urol 2003 44 : 650 655
5. Mellon JK. The finasteride prostate cancer prevention trial (PCPT) - what have we learned? Eur J Cancer 2005 41 : 2016 2022
6. Cohen YC, Liu KS, Heyden NL et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007 99 : 1366 1374
7. Tetu B, Srigley JR, Boivin JC et al. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Am J Surg Pathol 1991 15 : 111 120
8. Civantos F, Soloway MS, Pinto JE. Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol 1996 14 (Suppl. 2 22 31
9. Yang XJ, Lecksell K, Short K et al. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1999 53 : 696 700
10. Bostwick DG, Qian J, Civantos F, Roehrborn CG, Montironi R. Does finasteride alter the pathology of the prostate and cancer grading? Clin Prostate Cancer 2004 2 : 228 235
11. Lucia MS, Epstein JI, Goodman PJ et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007 99 : 1375 1383
12. Cussenot O, Azzouzi AR, Nicolaiew N et al. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed chemoprevention trials using 5-alpha-reductase inhibitors. Eur Urol 2007 52 : 1082 1087
13. Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ. Type 1 and type 2, 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 2008 53 : 244 252
14. Thomas LN, Douglas RC, Lazier CB et al. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol 2008 179 : 147 151
15. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 2003 57 : 134 139
16. Andriole G, Bostwick D, Brawley O et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004 172 : 1314 1317
17. Thompson IM, Chi C, Ankerst DP et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006 98 : 1128 1133
18. Thompson IM, Ankerst DP, Chi C et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005 294 : 66 70 (Pubitemid 41002840)
19. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA Jr., Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: A bias-adjusted modeling approach. Cancer Prev Res (Phila Pa) 2008 1 : 174 181
20. Kaplan SA, Roehrborn CG, Meehan AG et al. PCPT: evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology 2009 73 : 935 939